Evidence map›Paper›PMID 40175800›Full record

ArticleOncology and therapy2025

Shared Decision-Making for Advanced Renal Cell Carcinoma: Focus on Adverse Event Management of Axitinib Plus IO: A Vodcast.

Edwin M Posadas, Nancy Moldawer, Greg Biddulph, Dharanija Rao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Edwin M PosadasDivision of Medical Oncology, Department of Medicine, Cedars Sinai Medical Center and Center for Uro-Oncology Research Excellence (CURE), 8700 Beverly Blvd., Davis 2067, Los Angeles, CA, 90048, USA. edwin.posadas@csmc.edu.
Nancy MoldawerDivision of Medical Oncology, Department of Medicine, Cedars Sinai Medical Center and Center for Uro-Oncology Research Excellence (CURE), 8700 Beverly Blvd., Davis 2067, Los Angeles, CA, 90048, USA.
Greg BiddulphPatient Author, Idaho Falls, ID, USA.
Dharanija RaoPfizer Inc., New York, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Shared decision-making is essential to the care of patients with advanced renal carcinoma which can empower patients and help the healthcare team understand the patient's goals of care. An important topic during the shared-decision making process is identification and management of treatment-related adverse events. A patient author and two healthcare professionals with real-world experience provide insight into the importance of shared decision-making and its utility in the management of treatment-related adverse events in patients with renal cell carcinoma who are receiving axitinib in combination with an immunotherapy agent.

Indexed as

Advanced renal cell carcinomaAdverse event managementAxitinibImmunotherapyShared decision-making

Identifiers

PMID40175800
PMCPMC12130415

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.